Related Experiment Video
Updated: Jan 15, 2026
Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
Incidence of Endocrine and Exocrine Pancreatic Insufficiency after Minimally Invasive Parenchyma-Sparing
Dario Solinas1,2, Marco Dal Molin1, Brady A Campbell1
1From the Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD (Solinas, Dal Molin, Campbell, Zhang, Cameron, Shubert, Lafaro, Burkhart, Burns, He).
Background:
Minimally invasive parenchyma-sparing pancreatectomy (MI-PSP) is being increasingly adopted for benign and low-grade pancreatic tumors. We sought to evaluate whether this approach is associated with reduced incidence of postoperative diabetes mellitus (DM) and pancreatic exocrine insufficiency (PEI).
Study Design:
We conducted a retrospective single-institution analysis of patients undergoing minimally invasive pancreatectomy between 2006 and 2024 for benign and low-grade pancreatic tumors, defined as localized neoplasms with a low risk of metastases. Propensity score matching (1:1) was performed to compare MI-PSP and minimally invasive standard pancreatectomy (MI-P) based on age, sex, BMI, preoperative non-insulin-dependent DM, and tumor size. The risk of developing postoperative new-onset or worsening DM and PEI was assessed using a multivariable regression model.
Results:
A total of 184 patients were included. No significant difference emerged between the 2 groups regarding postoperative complications (Clavien-Dindo grade 3 or higher) within 90 days (p = 0.7). Among patients undergoing MI-P, 21 (23%) developed new-onset or worsening diabetes, with 11 (12%) requiring insulin. In contrast, among patients undergoing MI-PSP, only 9 (9.8%) developed new-onset or worsening diabetes, with 3 (3.3%) needing insulin treatment. The 5-year cumulative incidence risk of developing new-onset or worsening diabetes was 38.9% (95% CI 20.7 to 52.9) in the MI-P group and 26.7% (95% CI 7.5 to 42) in the MI-PSP group (p = 0.008). Similarly, PEI developed in 22% of MI-P vs 5.4% of MI-PSP patients (p = 0.001). In the multivariable analysis, patients undergoing MI-P exhibited a significantly higher risk of developing new-onset or worsening diabetes (hazard ratio 3.06, p = 0.006) and PEI (odds ratio 3.18, p = 0.037) compared with those receiving MI-PSP.
Conclusions:
MI-PSP was associated with a lower incidence of postoperative metabolic complications in the management of benign and low-grade pancreatic tumors.
Related Concept Videos
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment: